Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate Safety, Tolerability, PK and PD of Antisense Oligonucleotide AMX0114 Administered to Adult Participants With Amyotrophic Lateral Sclerosis

NCT06665165 is registered in ClinicalTrials.gov with Amylyx Pharmaceuticals Inc. as lead sponsor.

NCT NCT06665165
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06665165 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate Safety, Tolerability, PK and PD of Antisense Oligonucleotide AMX0114 Administered to Adult Participants With Amyotrophic Lateral Sclerosis
Lead sponsor
Amylyx Pharmaceuticals Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
April 7, 2025
Completion date
October 31, 2027
Enrollment
48 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

als